Company Encyclopedia
View More
name
DRTG
600329.SH
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1981 and is based in Tianjin, the People’s Republic of China.
3.136 T
600329.SHMarket value -Rank by Market Cap -/-

Financial Score

11/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking80/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE46.37%A
    • Profit Margin66.68%A
    • Gross Margin76.62%A
  • Growth ScoreD
    • Revenue YoY-33.26%E
    • Net Profit YoY283.72%A
    • Total Assets YoY5.61%B
    • Net Assets YoY39.82%A
  • Cash ScoreD
    • Cash Flow Margin149.98%C
    • OCF YoY-33.26%E
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreA
    • Gearing Ratio22.11%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%

    TJ DaRenTang released its 2025 semi-annual report, with revenue of 2.651 billion yuan, a year-on-year decrease of 33.15%; net profit attributable to the parent company was 1.928 billion yuan, a year-on-year increase of 193.08%. This was mainly due to the transfer of 12% equity in Tianjin Sike, resulting in a post-tax net gain of 1.308 billion yuan. The net profit excluding non-recurring items was 596 million yuan, a year-on-year decrease of 5.93%. After excluding the impact of investment income from joint ventures, the net profit attributable to the parent company excluding non-recurring items increased by 12.86% year-on-year

    Zhitong·
    SH
    600329
    +0.37%
    SG
    T14
    +0.32%
    Zhitong·
    SH
    600329
    +0.37%
    SG
    T14
    +0.32%

    Some traditional Chinese medicine stocks saw their net profits double year-on-year in the first half of the year

    As of now, 19 listed companies have released their semi-annual reports for 2025, among which companies like DRTG, JI LIN AO DONG, and BUCHANG PHARMA have seen their net profits double year-on-year. DRTG expects its net profit for the first half of the year to reach between 1.84 billion and 2 billion yuan, a year-on-year increase of 180% to 204%, mainly due to profits from equity sales. TMSP has turned losses into profits, with an overall improvement in profitability. The stock hit the daily limit today, with well-known speculative funds net buying 9.5309 million yuan

    Zhitong·
    SH
    600671
    -2.62%
    SH
    600329
    +0.37%
    SZ
    000623
    -0.68%
    Zhitong·
    SH
    600671
    -2.62%
    SH
    600329
    +0.37%
    SZ
    000623
    -0.68%

    TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease

    According to DRTG, the "Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease," led by the Chinese Association of Traditional Chinese Medicine and jointly formulated by national authoritative experts, has been released. Tongmai Yangxin Wan, a product under DRTG, has received a "strong recommendation" level recognition

    Zhitong·
    SH
    600329
    +0.37%
    SG
    T14
    +0.32%
    Zhitong·
    SH
    600329
    +0.37%
    SG
    T14
    +0.32%

    TJ DaRenTang: Expected net profit in the first half of 2025 to increase by 180%-204% year-on-year

    TJ DaRenTang announced that the company expects to achieve a net profit attributable to the owners of the parent company of RMB 1.84 billion to RMB 2 billion for the first half of 2025, an increase of RMB 1.182 billion to RMB 1.342 billion compared to the same period last year, representing a year-on-year increase of 180% to 204%. It is expected that the net profit attributable to the owners of the parent company, excluding non-recurring gains and losses, will be RMB 560 million to RMB 620 million for the first half of 2025, a decrease of RMB 73.83 million to RMB 13.83 million compared to the same period last year, representing a year-on-year decrease of 12% to 2%

    Zhitong·
    SH
    600329
    +0.37%
    SG
    T14
    +0.32%
    Zhitong·
    SH
    600329
    +0.37%
    SG
    T14
    +0.32%

    DRTG deepens cooperation with Huawei

    According to DRTG, on May 16th, the comprehensive deepening cooperation launch meeting between Tianyao DRTG and Huawei was held at the Tianyao Building. The company stated that this meeting marks the beginning of a comprehensive deepening of cooperation between Tianyao DRTG and Huawei. Both parties will fully leverage their respective advantages and ecological resources to jointly establish a digital and intelligent ecosystem for traditional Chinese medicine

    Zhitong·
    SH
    600329
    +0.37%
    Zhitong·
    SH
    600329
    +0.37%
    © 2025 Longbridge｜Disclaimer